Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
Evaluating Prostate Cancer with Multiparametric MRI
Brief description of study.
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer.
Detailed description of study
Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Prostate Carcinoma,Prostate Cancer
-
Age: 18 years - 100 years
-
Gender: Male
Inclusion Criteria
Recently diagnosed with prostate cancer for whom definitive surgical treatment is indicated
Exclusion Criteria
Not suitable to undergo MRI or receive gadolinium-based contrast agent (severe, untreatable claustrophobia; MRI-incompatible metallic objects or implanted medical devices; renal failure; weight greater than allowable by scanner per institutional standard practice)
Prior surgical and/or non-surgical treatment for prostate cancer
Prior hip replacement or other major pelvic surgery
This study investigates how multiparametric magnetic resonance imaging (MRI) can be used to evaluate the stage of prostate cancer and assist in planning treatment. Prostate cancer is a disease where cells in the prostate grow uncontrollably. Multiparametric MRI is a type of scan that uses different methods to create detailed images of the prostate, which may help in identifying aggressive forms of cancer.
Participants in the study will undergo a multiparametric MRI scan. This procedure involves using magnetic fields and radio waves to take pictures of the prostate. These images help doctors understand the cancer better and plan the most appropriate treatment.
- Who can participate: Men who have been recently diagnosed with prostate cancer and need surgical treatment may be eligible to participate. Individuals must be able to undergo an MRI and receive gadolinium-based contrast agent.
- Study details: Participants will undergo a scan to evaluate their prostate cancer.